Literature DB >> 1724637

Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

A N Wadworth1, K L Goa.   

Abstract

The antibacterial efficacy of oral lomefloxacin has been investigated in a wide variety of infections, including respiratory and uncomplicated and complicated urinary tract infections, obstetric, gynaecological, joint, skin, oral, ear, nose, throat and eye infections. It has also been used as an otic solution in patients with otitis media and as an ophthalmic solution in the treatment of eye infections. In clinical trials its efficacy is equivalent to that of other quinolones and it is at least as effective as other antibacterial drugs ordinarily used in these infections. Lomefloxacin offers certain advantages compared with other quinolone antibacterial drugs in that it may be conveniently administered once daily and theophylline dosage adjustment does not appear to be necessary in patients receiving this bronchodilator concomitantly. Thus, orally administered lomefloxacin should prove a useful broad spectrum antibacterial drug for a wide variety of clinical infections.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1724637     DOI: 10.2165/00003495-199142060-00009

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  126 in total

1.  Tissue penetration and pharmacokinetics of lomefloxacin following multiple doses.

Authors:  J Kavi; J Stone; J M Andrews; J P Ashby; R Wise
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-02       Impact factor: 3.267

2.  In vitro and in vivo activity of NY-198, a new difluorinated quinolone.

Authors:  T Hirose; E Okezaki; H Kato; Y Ito; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

Review 3.  Usual and unusual antibacterial effects of quinolones.

Authors:  Y X Furet; J C Pechère
Journal:  J Antimicrob Chemother       Date:  1990-10       Impact factor: 5.790

4.  Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.

Authors:  I Shalit; S A Berger; A Gorea; H Frimerman
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

Review 5.  Bacterial resistance to fluoroquinolones.

Authors:  H C Neu
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

6.  Inhibition of the oxidative metabolism of theophylline in isolated rat hepatocytes by the quinolone antibiotic enoxacin and its metabolite oxoenoxacin, but not by ofloxacin.

Authors:  G J Mulder; J F Nagelkerke; R B Tijdens; W J Wijnands; E J Van der Mark
Journal:  Biochem Pharmacol       Date:  1988-07-01       Impact factor: 5.858

7.  [Comparison of clinical efficacy of lomefloxacin (LFLX, NY-198) and pipemidic acid (PPA) in the treatment of infectious enteritis by a double-blind method. The Japan Research Committee of Lomefloxacin Research Group Enteritis].

Authors:  T Aoki; N Shimizu; I Tomizawa; Y Takizawa; Y Matsubara; Y Nitta; H Sagara; T Seo; N Kanehisa; M Murata
Journal:  Kansenshogaku Zasshi       Date:  1989-06

8.  Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice.

Authors:  Y Obana; T Nishino
Journal:  Drugs Exp Clin Res       Date:  1988

9.  4-quinolones inhibit biotransformation of caffeine.

Authors:  S Harder; A H Staib; C Beer; A Papenburg; W Stille; P M Shah
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

10.  Comparative in vitro activity of lomefloxacin (SC 47111 or NY-198) against fresh clinical bacterial isolates.

Authors:  D N Wright; B Saxon; J M Matsen
Journal:  Diagn Microbiol Infect Dis       Date:  1989 May-Jun       Impact factor: 2.803

View more
  11 in total

Review 1.  Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  J A Balfour; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

2.  Safety and efficacy of lomefloxacin versus norfloxacin in the treatment of complicated urinary tract infections.

Authors:  I M Hoepelman; W H Havinga; R A Benne; M Zwinkels; M A de Wit; H A de Hond; T A Boon; M R Visser; F W van Asbeck; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

3.  Enantioseparation of lomefloxacin hydrochloride by high-speed counter-current chromatography using sulfated-β-cyclodextrin as a chiral selector.

Authors:  Yun Wei; Shijuan Du; Yoichiro Ito
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-09-15       Impact factor: 3.205

Review 4.  Safety and tolerability of fluoroquinolones.

Authors:  S R Norrby; P S Lietman
Journal:  Drugs       Date:  1993       Impact factor: 9.546

5.  Safety of fluoroquinolones: An update.

Authors:  L Mandell; G Tillotson
Journal:  Can J Infect Dis       Date:  2002-01

6.  Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections.

Authors:  J M Kovarik; A I Hoepelman; J M Smit; P A Sips; M Rozenberg-Arska; J H Glerum; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

7.  Topical Lomefloxacin versus Topical Chloramphenicol in the Treatment of Acute Bacterial Conjunctivitis.

Authors:  A Agius-Fernandez; A Patterson; M Fsadni; A Jauch; P S Raj
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 8.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

Review 9.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

Review 10.  Quinolone antibacterials. An update of their pharmacology and therapeutic use.

Authors:  N von Rosenstiel; D Adam
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.